Ramakrishna BVR has been appointed as Strategic Business Unit (SBU) Head – Paedia /ENT Business at Sun Pharma, marking a dynamic step forward in his accomplished pharmaceutical career. With over two decades of deep industry experience, Ramakrishna brings a solid track record of building businesses, reviving brands, and leading large-scale sales and marketing teams across therapeutic areas.
In his new role, he will spearhead the Paediatrics vertical at Sun Pharma, overseeing growth strategy, brand positioning, and market expansion for the Paedia business. Known for his people-first leadership style and sharp market acumen, Ramakrishna is poised to drive innovation and growth in a segment that plays a crucial role in paediatric health across India and beyond.
Before this, Ramakrishna served as Director – Business Head (Acute Business) at Cipla, where he successfully led one of the company’s most dynamic therapy clusters. His earlier stints include over six impactful years at Alkem Laboratories Ltd., rising from National Sales Manager to General Manager, and key roles at Intas Pharmaceuticals, Abbott, and Ranbaxy, where he managed ₹100+ crore portfolios and several iconic brands in acute and hospital care.
His career has spanned leadership roles across geographies, including Nagpur, Hyderabad, Ahmedabad, and Mumbai—always leaving a mark with his consistent ability to deliver results, drive sales transformation, and build strong commercial teams. His journey from regional management to SBU leadership reflects not just expertise, but resilience, adaptability, and a passion for delivering quality healthcare at scale.
With this transition to Sun Pharma, Ramakrishna BVR steps into a role that will allow him to shape the future of paediatric care in one of India’s most respected pharmaceutical giants. Here’s wishing him success as he embarks on this new chapter leading the Paedia Business at Sun Pharma.